Eli Lilly (LLY.US) stops muscle protective drug diabetes research, Zepbound combination plan affected.

Zhitong Finance APP learned that pharmaceutical giant Eli Lilly (LLY.US) has halted experimental drug research aimed at preventing muscle loss in obese patients, citing strategic business considerations.